{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:10:49Z","timestamp":1788793849263,"version":"build-2803163510"},"reference-count":18,"publisher":"Norwegian Medical Association","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.26.0122","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:00:12Z","timestamp":1781100012000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical and non-clinical use of MDMA"],"prefix":"10.4045","volume":"146","author":[{"given":"Tor-Morten","family":"Kvam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar W.","family":"Goks\u00f8yr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowan H.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Berthold-Losleben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Autran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole A.","family":"Andreassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Nichols\u00a0DE. Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated. Front Psychiatry 2022; 13: 863088. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35401275&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffpsyt.2022.863088","DOI":"10.3389\/fpsyt.2022.863088"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Wolfgang\u00a0AS, Fonzo\u00a0GA, Gray\u00a0JC et al. MDMA and MDMA-Assisted Therapy. Am J Psychiatry 2025; 182: 79\u2013103. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39741438&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1176%2Fappi.ajp.20230681","DOI":"10.1176\/appi.ajp.20230681"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Nardou\u00a0R, Lewis\u00a0EM, Rothhaas\u00a0R et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature 2019; 569: 116\u201320. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30944474&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41586-019-1075-9","DOI":"10.1038\/s41586-019-1075-9"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Wagner\u00a0MT, Mithoefer\u00a0MC, Mithoefer\u00a0AT et al. Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol 2017; 31: 967\u201374. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28635375&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881117711712","DOI":"10.1177\/0269881117711712"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"O'Donnell\u00a0KC, Okano\u00a0L, Alpert\u00a0M et al. The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD. Front Psychol 2024; 15: 1427531. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39559692&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffpsyg.2024.1427531","DOI":"10.3389\/fpsyg.2024.1427531"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Jerome\u00a0L, Feduccia\u00a0AA, Wang\u00a0JB et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl) 2020; 237: 2485\u201397. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32500209&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00213-020-05548-2","DOI":"10.1007\/s00213-020-05548-2"},{"key":"ref=7","unstructured":"Mitchell\u00a0JM, Bogenschutz\u00a0M, Lilienstein\u00a0A et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021; 27: 1025\u201333. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33972795&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41591-021-01336-3"},{"key":"ref=8","unstructured":"Mitchell\u00a0JM, Ot'alora G\u00a0M, van der Kolk\u00a0B et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 2023; 29: 2473\u201380. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37709999&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41591-023-02565-4"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Schnurr\u00a0PP, Chard\u00a0KM, Ruzek\u00a0JI et al. Comparison of Prolonged Exposure vs Cognitive Processing Therapy for Treatment of Posttraumatic Stress Disorder Among US Veterans: A Randomized Clinical Trial. JAMA Netw Open 2022; 5: e2136921. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35044471&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjamanetworkopen.2021.36921","DOI":"10.1001\/jamanetworkopen.2021.36921"},{"key":"ref=10","unstructured":"Reardon\u00a0S. MDMA therapy for PTSD rejected by FDA panel. Nature 2024; PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38844808&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fd41586-024-01622-3"},{"key":"ref=11","unstructured":"Kvam\u00a0T-M, Goks\u00f8yr\u00a0IW, Rog\u00a0J et al. MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study - CORRIGENDUM. Br J Psychiatry 2026; 228: 1. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41664469&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1192%2Fbjp.2026.10551"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Kvam\u00a0T-M, Goks\u00f8yr\u00a0IW, Rog\u00a0J et al. MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial. J Psychiatr Res 2026; 193: 302\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41344230&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jpsychires.2025.11.030","DOI":"10.1016\/j.jpsychires.2025.11.030"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Griesler\u00a0PC, Hu\u00a0MC, Wall\u00a0MM et al. Medical Use and Misuse of Prescription Opioids in the US Adult Population: 2016-2017. Am J Public Health 2019; 109: 1258\u201365. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31318593&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2105%2FAJPH.2019.305162","DOI":"10.2105\/AJPH.2019.305162"},{"key":"ref=14","unstructured":"Folkehelseinstituttet. Narkotikabruk i Norge. https:\/\/www.fhi.no\/le\/rusmidler-og-avhengighet\/narkotikainorge\/bruk-av-narkotika\/narkotikabruk-i-norge\/ Lest 30.4.2026."},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Marseille\u00a0E, Mitchell\u00a0JM, Kahn\u00a0JG. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. PLoS One 2022; 17: e0263252. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35213554&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371%2Fjournal.pone.0263252","DOI":"10.1371\/journal.pone.0263252"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Hutchison\u00a0KE, Hooper\u00a0JF, Karoly\u00a0HC. Psilocybin Outside the Clinic: Public Health Challenges of Increasing Publicity, Accessibility, and Use. JAMA Psychiatry 2026; 83: 78\u201384. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41191341&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjamapsychiatry.2025.3038","DOI":"10.1001\/jamapsychiatry.2025.3038"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Gr\u00f8nner\u00f8d\u00a0C, R\u00f8nningen\u00a0T, Haugsj\u00e5\u00a0IR et al. Recreational MDMA use in Norway: results from an internet convenience sample. Front Psychiatry 2025; 16: 1619676. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41080781&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffpsyt.2025.1619676","DOI":"10.3389\/fpsyt.2025.1619676"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Haridy\u00a0R. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature 2023; 619: 227\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37386185&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fd41586-023-02093-8","DOI":"10.1038\/d41586-023-02093-8"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Klinisk og ikke-klinisk bruk av MDMA"],"language":"no","deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:48:39Z","timestamp":1788792519000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2026\/06\/kronikk\/klinisk-og-ikke-klinisk-bruk-av-mdma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.26.0122","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}